|
Apr 5
|
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
|
|
Apr 5
|
UPDATE 2-US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer
|
|
Apr 5
|
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
|
|
Apr 5
|
Bristol Myers CAR-T therapy approved by FDA for earlier myeloma use
|
|
Apr 4
|
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
|
|
Apr 4
|
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
|
|
Apr 4
|
Merck puts KRAS cancer drug competitor to the test
|
|
Apr 4
|
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
|
|
Apr 3
|
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
|
|
Apr 3
|
Bristol-Myers Squibb (NYSE:BMY) investors are sitting on a loss of 20% if they invested a year ago
|
|
Apr 3
|
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
|
|
Apr 2
|
Bristol Myers Squibb (BMY) Stock Moves -0.47%: What You Should Know
|
|
Apr 2
|
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
|
|
Apr 1
|
The Bargain Hunter’s Dream: 3 Underpriced Stocks Poised for Massive Gains
|
|
Apr 1
|
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
|
|
Mar 30
|
Income Investors Should Know That Bristol-Myers Squibb Company (NYSE:BMY) Goes Ex-Dividend Soon
|
|
Mar 29
|
Bristol Myers says KRAS drug succeeds in key trial
|
|
Mar 28
|
UPDATE 1-Bristol Myers' bowel disease drug fails to meet main goal in late-stage study
|
|
Mar 28
|
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…
|
|
Mar 28
|
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
|